Register for our free email digests:
Latest From Alkermes PLC
Otsuka claimed Alkermes' Aristada is 'legally equivalent' to Abilify but DC Circuit deferred to FDA's finding that the two have different active moieties and thus Abilify's three-year exclusivity does not apply to Aristada.
Failure of NSI-189 in major depression study sends stock price down about 50% and next steps for development are unclear.
Nektar taps into Lilly's immunology know-how for fast development of NKTR-358, which targets IL-2 to stimulate the body's own inflammation-inhibiting Tregs rather than suppress the immune system.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
- Large Molecule
- Nanotechnology, Chips, etc.
- Controlled Release
- Drug Delivery
- Therapeutic Areas
- Musculoskeletal & Connective Tissue Disorders
- Neurology, Nervous System
- Alkermes Inc.
- Western Europe
- Parent & Subsidiaries
- Alkermes PLC
- Senior Management
Richard F Pops, Chmn. & CEO
James M Frates, SVP, CFO
Elliot W Ehrich, MD, EVP, R&D & CMO
Blair C Jackson, VP, Bus. Dev.
Mark Stejbach, SVP, Chief Commercial Officer
- Contact Info
Phone: 1 772 8000
1 Burlington Rd.
Dublin 4, MA
You must sign in to use this functionality
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.